New drug could boost brain recovery after stroke
NCT ID NCT07552610
First seen Jun 25, 2026 · Last updated Jun 25, 2026
Summary
This study tests whether adding sivelestat sodium to standard clot-removal treatment helps people recover better after a stroke caused by a large blockage in the brain. The drug aims to reduce inflammation that can damage brain tissue even after blood flow is restored. About 868 adults aged 18-80 will take part, receiving either the drug or a placebo for up to 7 days. The main goal is to see if more people achieve independence (no or minimal disability) after 90 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Xuanwu Hospital, Capital Medical University.
Beijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sivelestat sodium
What this could lead to
If it works, this could reduce brain damage and improve recovery after stroke by calming inflammation caused by the body's immune cells.
What could go wrong
This is an early-stage trial with no phase assigned, so results are uncertain. The drug may not improve outcomes or could cause side effects like bleeding or infection.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.